Real World Designs in Economic Evaluation
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (5) , 449-458
- https://doi.org/10.2165/00019053-199916050-00003
Abstract
This paper identifies the information that economic evaluation should provide to adequately inform policy-makers. First, policy-makers need cost-effectiveness information that is both internally and externally valid. The latter aspect is often ignored and refers to the relevance of the results of economic trials to the specific decision-making context of the policy-maker. Second, policy-makers, like purchasers of care, may want assessments of the overall budget and health impacts of adopting an intervention in a disease or treatment area. This requires more of an aggregate analysis than the current approaches to economic evaluation (which are typically individual-orientated). There are 3 main conceptual approaches to economic evaluation: the use of randomised controlled trials (RCTs), observational studies and modelling. The RCT can be considered as the gold standard in economic evaluation because of its high internal validity, but results should be interpreted with caution because of its low external validity. There a number of options to enhance external validity; of these, additional modelling and observational data seem to be the most promising. To address issues at the system level, disease modelling or public health modelling is suggested. A 3-step approach, comprising successive assessment of internal validity, external validity (real world relevance) and net impact at the system level, can enhance the informative value of economic analyses. For example, this approach has been used to assess the informative value to decision-makers of an RCT in benign prostatic hyperplasia. The analysis emphasised the feasibility and importance of additional modelling beyond the results from an RCT-based economic analysis and provided important information of relevance for policy-making. Because of the need to increase the realworld relevance of pharmacoeconomic analyses, there is potentially a large role for modelling in economic evaluation; however, in order to enhance its credibility, more attention should be paid to validity aspects.Keywords
This publication has 22 references indexed in Scilit:
- A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapyHealth Economics, 1997
- Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working GroupPublished by American Medical Association (AMA) ,1997
- Modelling in Ecomomic Evaluation: An Unavoidable Fact of LifeHealth Economics, 1997
- Problems of using modelling in the economic evaluation of health careHealth Economics, 1996
- The Journal's Policy on Cost-Effectiveness AnalysesNew England Journal of Medicine, 1994
- Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population LevelInternational Journal of Technology Assessment in Health Care, 1994
- Economic impact of the AIDS epidemic in the European CommunityAIDS, 1993
- Cost‐effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status?Health Economics, 1992
- The learning curve and the cost of heart transplantation.1992
- Sleeping giant.1991